menu
    • menu
    [{"orgOrder":0,"company":"Asana BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Gusacitinib","moa":"JAK","graph1":"Dermatology","graph2":"Phase II","graph3":"Asana BioSciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Asana BioSciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Asana BioSciences \/ Inapplicable"},{"orgOrder":0,"company":"Asana BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Gusacitinib","moa":"JAK","graph1":"Dermatology","graph2":"Phase II","graph3":"Asana BioSciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Asana BioSciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Asana BioSciences \/ Inapplicable"},{"orgOrder":0,"company":"Asana BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Gusacitinib","moa":"JAK","graph1":"Dermatology","graph2":"Phase II","graph3":"Asana BioSciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Asana BioSciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Asana BioSciences \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Gusacitinib

    Menu

    Gusacitinib

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
    filter

    Year

    filter

    DEALS // DEV.

    filter

    Country

    filter
    Sponsor
    filter

    Therapeutic Area

    filter

    Study Phase

    filter

    Deal Type

    filter

    Product Type

    filter

    Dosage Form

    filter

    Lead Product

    filter

    Target

    refresh Filters
    refresh Reset Filter
    refresh Reset Filter
    price-trend All Developments

    Therapeutic Area by Lead Product

    ForexGraph

    Study Phase by Lead Product

    ForexGraph

    Company by Lead Product

    ForexGraph

    Top Deals by Deal Size (USD bn)

    ForexGraph

    01

    Asana BioSciences

    U.S.A arrow
    AAN
    Not Confirmed

    Asana BioSciences

    U.S.A arrow
    AAN
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Gusacitinib

    Therapeutic Area : Dermatology

    Study Phase : Phase II

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Asana BioSciences to Present Additional Efficacy Data from Chronic Hand Eczema Phase 2b Trial of Gusacitinib a...

    Details : Asana BioSciences will present additional positive results from a Phase 2b study evaluating the efficacy and safety of its investigational oral JAK kinase family and SYK tyrosine kinase inhibitor gusacitinib in adult patients with moderate-to-severe chro...

    Product Name : ASN002

    Product Type : Other Small Molecule

    Upfront Cash : Inapplicable

    April 21, 2021

    Lead Product(s) : Gusacitinib

    Therapeutic Area : Dermatology

    Highest Development Status : Phase II

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    02

    Asana BioSciences

    U.S.A arrow
    AAN
    Not Confirmed

    Asana BioSciences

    U.S.A arrow
    AAN
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Gusacitinib

    Therapeutic Area : Dermatology

    Study Phase : Phase II

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Asana BioSciences to Present Positive Results from Phase 2b Study of Oral JAK/SYK Inhibitor Gusacitinib in Pat...

    Details : Gusacitinib achieved rapid, dose-dependent, clinically meaningful, and statistically significant improvement relative to placebo in both the primary and key secondary endpoints of efficacy as early as 2 weeks and the effects were sustained for the durati...

    Product Name : ASN002

    Product Type : Other Small Molecule

    Upfront Cash : Inapplicable

    October 20, 2020

    Lead Product(s) : Gusacitinib

    Therapeutic Area : Dermatology

    Highest Development Status : Phase II

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    03

    Asana BioSciences

    U.S.A arrow
    AAN
    Not Confirmed

    Asana BioSciences

    U.S.A arrow
    AAN
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Gusacitinib

    Therapeutic Area : Dermatology

    Study Phase : Phase II

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Asana BioSciences Announces Topline Results from Phase 2b Study of Oral JAK/SYK Inhibitor Gusacitinib in Patie...

    Details : The topline results show that gusacitinib achieved a dose dependent, clinically meaningful, andstatistically significant improvement relative to placebo in both the primary and key secondary endpoints of efficacy.

    Product Name : ASN002

    Product Type : Other Small Molecule

    Upfront Cash : Inapplicable

    February 06, 2020

    Lead Product(s) : Gusacitinib

    Therapeutic Area : Dermatology

    Highest Development Status : Phase II

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth